Biomarin Pharmaceutical Inc., of San Rafael, Calif., said the FDA granted Kuvan (sapropterin dihydrochloride) powder for oral solution and tablets a six-month pediatric exclusivity extension. The action extends the product's market exclusivity to June 2015 and is based on studies submitted in response to a written request by the FDA to investigate the use of Kuvan in pediatric patients from birth to age 6.